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Abstract
Background: Mucin alterations are a common feature of esophageal neoplasia, and alterations in
MUC2 mucin have been associated with tumor progression in the esophagus. Bile acids have been
linked to esophageal adenocarcinoma and mucin secretion, but their effects on mucin gene
expression in human esophageal adenocarcinoma cells is unknown.
Methods: Human esophageal adenocarcinoma cells were treated 18 hours with 50–300 μM
deoxycholic acid, chenodeoxycholic acid, or taurocholic acid. MUC2 transcription was assayed
using a MUC2 promoter reporter luciferase construct and MUC2 protein was assayed by Western
blot analysis. Transcription Nuclear factor-κB activity was measured using a Nuclear factor-κB
reporter construct and confirmed by Western blot analysis for Nuclear factor-κB p65.
Results: MUC2 transcription and MUC2 protein expression were increased four to five fold by
bile acids in a time and dose-dependent manner with no effect on cell viability. Nuclear factor-κB
activity was also increased. Treatment with the putative chemopreventive agent aspirin, which
decreased Nuclear factor-κB activity, also decreased MUC2 transcription. Nuclear factor-κB p65
siRNA decreased MUC2 transcription, confirming the significance of Nuclear factor-κB in MUC2
induction by deoxycholic acid. Calphostin C, a specific inhibitor of protein kinase C (PKC), greatly
decreased bile acid induced MUC2 transcription and Nuclear factor-κB activity, whereas inhibitors
of MAP kinase had no effect.
Conclusion:  Deoxycholic acid induced MUC2 overexpression in human esophageal
adenocarcinoma cells by activation of Nuclear factor-κB transcription through a process involving
PKC-dependent but not PKA, independent of activation of MAP kinase.
Background
Changes in the characteristics of the surface epithelial
mucins is the hallmark of Barrett's metaplasia, dysplasia
and adenocarcinoma of esophagus[1,2]. MUC2, a high
molecular weight glycoprotein, is the major secreted
mucin in the large and small intestine[3,4]. Human
esophageal adenocarcinoma and cell lines derived from
tumors can differ significantly in the amount of MUC2
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mucin synthesized and these differences correlate with
altered biochemical and biologic properties including
those with relevance to invasion and metastasis, MUC2 is
expressed in esophageal carcinoma cell lines, and patients
with esophageal carcinomas characteristically present
with advanced-stage disease[1,5,6].
Bile acids, fractions of duodenogastricoesophageal reflux
(DGER) have been detected in patients with extensive
esophageal mucosal damage, have been reported to pro-
mote esophageal carcinogenesis[7,8]. These bile acids,
primarily deoxycholic acid (DCA), are cytotoxic to
esophageal cells[8], and are established tumor promoters
in animal models[9]. In esophageal adenocarcinoma,
DCA is believed to contribute to carcinogenesis during
reflux where reluxates enter the lower esophagus[10]. Bile
acids also have been reported to stimulate invasion and
metastasis of esophageal carcinoma cells via activation of
multiple signaling pathways [11-13]. Although regula-
tions of MUC1 and MUC4 mucin genes by bile acids, such
as DCA, CDCA and TCA, in human oesophageal cancer
cells have been the thorough extensive study [14-16], the
mechanisms responsible for regulation of MUC2 expres-
sion in the esophageal adenocarcinoma cells remain
unknown.
In the current study, we sought to determine the effects of
bile acids on MUC2 gene expression in esophageal aden-
ocarcinoma cells and the molecular mechanisms
involved. We find that bile acids induce MUC2 expression
in human esophageal adenocarcinoma cells at the level of
transcription through a process that involves protein
kinase C (PKC)-dependent activation of Nuclear factor-κB
(NF-κB), primarily a MAP kinase-independent.
Methods
Materials
Deoxycholic acid (DCA), chenodeoxycholic acid (CDCA),
and taurocholic acid (TCA) were obtained from Sigma (St.
Louis, USA). CAPE, Calphostin C, U0126 (1,4-diamino-2,
3-dicyano-1,4-bis(2-aminophenylthio)butadiene),
PD98059 (2'-amino-3'-methoxyflavone), and H-8 (PKA
inhibitor) (N-[2-(methylamino)ethyl]-5-isoquinolinesul-
fonamide dihydrochloride) were purchased from Calbio-
chem (San Diego, CA). Mouse monoclonal antibody
(MoAb) CCP-58, specific for MUC2 glycoprotein, was
obtained from Novocastra (Newcastle, UK). Antibodies
for Nuclear factor-κB (NF-κB) p65, extracellular signal-
regulated kinase (ERK1/2), JNK, P38 and phospho-ERK1/
2, JNK, P38 were obtained from Cell Signaling Technol-
ogy (Beverly, MA), aspirin, secondary antibodies and anti-
beta-actin MoAb was obtained from Sigma (USA).
FuGENE 6 transfection reagent was from Roche (Indiana-
polis, IN).
Cell Culture and Treatment
SEG-1 is a BE adenocarcinoma cell line, the cell line were
cultured in Dulbecco's Modified Eagle Medium (Invitro-
gen, Carlsbad, Calif) supplemented with 10% heat-inacti-
vated fetal bovine serum (Invitrogen) and 100 U/mL
penicillin G and 100 μg/mL streptomycin (Invitrogen) at
37°C in a humidified incubator containing 5% carbon
dioxide.
SEG-1 cells were plated in regular medium for 36 hours.
The medium was then replaced with 0.5% FBS for an
additional 24 hours. Cultures were then treated with bile
acids. For inhibitor assays, SEG-1 cells were pretreated
with inhibitors for 1 hour before exposure to DCA for an
additional 18 hours. Calphostin C was used under a fluo-
rescent lamp of 13 W located 15 cm above the plates.
For determining the effects of bile acids on viability, cells
were treated for 24 hours with ≤ 200 μM DCA, CDCA, or
TCA, then detected with The CellTiter-Fluor™ Assay
kit(Promega BioSciences, San Luis Obispo, CA), accord-
ing to the manufacturer's protocol
Protein Extraction and Western Blotting
Cellular proteins from treated SEG-1 cells were prepared
in 40 mM Tris-HCI, pH 6.9, 150 mM NaCl, 2 mM ethyl-
enediaminetetraacetic acid, 100 mM sodium fluoride, 10
mM sodium pyrophosphate, 2 mM orthovanadate, 1%
Triton X-100, 1% Nonidert P40 (NP-40), 0.3 mM phenyl-
methanesulfonyl fluoride, and 1 mini tablet protein
inhibitor (sigma, USA). Separate cytosol and nuclear pro-
tein lysates were prepared by using the Active Motif
Nuclear Extract Kit (Active Motif Europe, Rixensart, Bel-
gium), according to the manufacturer's protocol. For rou-
tine quantitation of proteins, following the
manufacturer's protocol (Pierce, Rockford, IL). Equal
amounts of protein samples were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis on
either 3–8% Tris-acetate gradient gels for MUC2 detection
or 10% Tris-glycine gels for detection of other proteins.
After gel electrophoresis and transfer to nitrocellulose, the
membranes were stained in 0.5% Ponceau S with 1% ace-
tic acid to confirm the equal loading and transfer effi-
ciency. Membranes were incubated at 4°C overnight in a
blocking solution containing 5% bovine skim milk and
0.1% Tween 20 (Fischer Scientific, Pittsburgh, PA) in TBS
(10 mM Tris-HCl with 150 mM NaCl, pH 7.6), then
probed with specific primary and secondary antibodies
conjugated to horseradish peroxidase. Immunoreactive
bands were visualized by chemiluminescence solution
and exposure to X-ray film.
RNA Isolation and RT-PCR
Total RNA was isolated using TriReagent (Molecular
Research Center Inc.), and 3 μg was primed with randomBMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
Page 3 of 10
(page number not for citation purposes)
hexamers and reverse transcribed using Superscript II
(Invitrogen) in a final volume of 50 μl. One microliter of
this mixture was PCR-amplified in a 10 μl reaction using
AmpliTaq DNA polymerase (Applied Biosystems) with
the addition of 5% dimethyl sulfoxide. Primers for MUC2
were (forward) 5'-TGC CTG GCC CTG TCT TTG-3' and
(reverse) 5'-CAG CTC CAG CAT GAG TGC-3'; NF-κB p65
were (forward) 5'-GCG AGA GGA GCA CAG ATA CC-3'
and (reverse) 5'-CTG ATA GCC TGC TCC AGG TC-3'. The
PCR reaction mixture was denatured at 95°C for 5 min
followed by 30 cycles at 93°C for 30 s, 60°C for 30 s, and
72°C for 30 s. Alternatively, blocked and unblocked prim-
ers for beta-actin (forward) 5'-ATC TGG CAC CAC ACC
TTC TAC AAT GAG CTG C-3'; (reverse) 5'-CGT CAT ACT
CCT GCT TGC TGA TCC ACA TCT G-3' were used to
amplify this message as an internal control. All the prim-
ers were synthesized by Sangon (Shanghai, China). All
PCR products were analysed by Gel-Pro analyser version
3.1 software.
Transient Transfection and Luciferase Reporter Assays
Plasmids were prepared using the Genopure plasmid midi
kit from Roche (Indianapolis, IN). Methods to measure
the MUC2 promoter activity with luciferase as a reporter
have been reported previously [17-19]. Upstream frag-
ments of 2665 base pair (bp) from immediately adjacent
to the 5' translation start site of human MUC2 [GenBank
accession number U67167] [17] were generated by rou-
tine polymerase chain reaction from human genomic
DNA, using the following primer pairs (forward) 5'-GAG-
GCTAGCCCGGGCTTCCTGGTGAGTC-3', and (reverse)
5'-GAGCTCGAGCATGGTGGCTGGCAGGGGC-3'. The
2665-bp fragment was then inserted upstream of the luci-
ferase reporter in the pGL3-basic vector, according to the
instructions provided by the manufacturer (Promega).
DNA sequencing was performed to verify the correct
clone.
NF-κB transient transfection assays have been reported
previously[20,21]. The cells were transfected using the
SuperFect reagent (Qiagen) with a NF-kB  luciferase
reporter (Clontech) plasmid and a SV40 promoter-driven
beta-galactosidase expression plasmid to normalize the
transfection efficiency. After additional 24 h, the cells
were harvested in phosphate-buffered saline, lysed in luci-
ferase lysis buffer (Promega), and assayed for luciferase
and beta-galactosidase activities using the Promega luci-
ferase assay system (Promega).
For transient transfection, SEG-1 cells were seeded at a
concentration of 6 × 105 cells per well in 6-well plates.
After overnight, the cells in each well were transfected
with DNA (3 μg of MUC2 or NF-κB-luciferase reporter
plasmid and 0.2 μg of pCH110) by using 3 μL of
FuGENE6 (Roche) by following the manufacturer's proto-
col. After a 24-hour exposure to the transfection mixture,
the cells were incubated in medium containing 10% FBS
and different concentrations of bile acids or inhibitors for
an additional 18 hours and then harvested for measure-
ment of beta-galactosidase activity and luciferase activity.
The latter was measured by using the Promega luciferase
assay system according to the manufacturer's protocol
using a TriStar LB941 (Berthold; Germany). Luciferase
was normalized to the beta-galactosidase activity to
account for differences in transfection efficiency.
NF-κB p65 siRNA Transfection
SignalSilence NF-κB p65 siRNA was purchased from Cell
Signaling Technology (Danvers, MA). siCONTROL non-
targeting siRNA purchased from Dharmacon (Chicago,
IL) was used as a control siRNA. Cells were transfected
with siRNA using Oligofectamine transfection reagent
(Invitrogen) for 72 h according to the manufacturer's
instructions. To confirm the efficacy of NF-κB p65 siRNA,
NF-κB p65 mRNA and protein were analyzed using RT-
PCR and Western Blotting. The cytotoxic effect of NF-κB
p65 siRNA on SEG-1 cells was determined by CellTiter-
Fluor™ Assay (Promega, Madison, WI) according to the
manufacturer's protocol.
Statistical Analyses
Results were expressed as means ± SD, and statistical sig-
nificance was determined using by ANOVA. Differences of
P < 0.05 were considered significant. All experiments were
performed in triplicate.
Results
Effects of Bile Acids on MUC2 Expression and 
Transcription
SEG-1 treated with DCA, CDCA, and TCA. Viability of
SEG-1 cells was not significantly affected by treatment for
24 hours with 200 μM DCA (data not shown). The addi-
tion of DCA in 50–300 μM for 18 hours to SEG-1
increased MUC2 protein expression in a dose-dependent
manner with a maximum increase of approximately 4-
fold (Fig. 1a). Different bile acids may have different bio-
logic effects[22,23]. To examine the effects of different
bile acids on MUC2 induction, we treated SEG-1 with
DCA, CDCA, and TCA for 18 hours at a concentration of
100  μM. As shown in Figure 1a, all three bile acids
increased MUC2 protein expression, with DCA having the
strongest effect.
To determine whether bile acids increase MUC2 promoter
activity, we employed an MUC2 promoter luciferase con-
struct, which contains a 2205-bp human MUC2 5'-flank-
ing region fused to a luciferase reporter gene. After
transient transfection, cells were treated with different
concentrations of bile acid and luciferase activities were
determined (Fig. 1b). DCA induced MUC2 promoter-BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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driven luciferase activities in a dose-dependent manner in
SEG-1 cells, with a maximum 4–5 fold increase with 300
μM DCA. All tested bile acids induced MUC2 transcrip-
tion activity to a varying extent at a concentration of 100
μM for 18 hours.
Effects of Bile Acids on NF-κB Expression and 
Transcription
We evaluated NF-κB p65 protein levels and gene tran-
scription in the esophageal adenocarcinoma cell line.
SEG-1 treated with DCA in 50–300 μM for 18 hours to
SEG-1 increased NF-κB p65 protein expression in a dose
dependent fashion with a maximum increase of approxi-
mately 5-fold (Fig. 2a).
To examine the effects of different bile acids on NF-κB
induction, we treated SEG-1 with DCA, CDCA, and TCA
for 18 hours at a concentration of 100 μM. As shown in
Figure 2a, all three bile acids increased NF-κB p65 protein
expression, with DCA having the strongest effect.
To determine whether bile acids increase NF-κB gene tran-
scription, we employed a NF-κB promoter luciferase con-
struct, luciferase reporter gene driven by the NF-κB
promoter, was transiently transfected into SEG-1. After 24
hours, the transfected cells were treated with increasing
doses of DCA and with different bile acids in 100 μM for
18 hours (Fig. 2b). DCA induced NF-κB promoter-driven
luciferase activities in a dose dependent manner in SEG-1
cells, with a maximum 5–6 fold increase at a concentra-
tion of 300 μM. All tested bile acids induced NF-κB luci-
ferase activities to a varying extent at a concentration of
100 μM for 18 hours, with DCA having the strongest effect
(Fig. 2b), a result consistent with induction of MUC2
expression (Fig. 1b).
Requirement of NF-κB for Induction of MUC2 by DCA
Previous reports have suggested that NF-κB is important
in mediating bile acids signaling[8,24]. We therefore
assessed the effect of NF-κB on expression of MUC2
Effect of bile acids on MUC2 expression Figure 1
Effect of bile acids on MUC2 expression. (a) SEG-1 cells 
were treated for 18 hours with 50–300 μM DCA (left) or 
with 100 μM DCA, CDCA, or TCA (right). Total cellular 
protein was isolated and subjected to Western blotting for 
MUC2 and β-actin. (b) SEG-1 cells were transfected with 
MUC2 promoter luciferase construct, then treated for 18 
hours with 50–300 μM DCA (left) or with 100 μM DCA, 
CDCA, or TCA (right). Luciferase activity for the MUC2 
reporter was measured and normalized to beta-galactosidase 
activity. Values shown represent the means ± SD of triplicate 
experiments.
Effect of bile acids on Nuclear factor-κB (NF-κB) expression Figure 2
Effect of bile acids on Nuclear factor-κB (NF-κB) 
expression. (a) SEG-1 cells were treated for 18 hours with 
50–300 μM DCA (left) or with 100 μM DCA, CDCA, or 
TCA (right). Cellular nuclear protein was subjected to West-
ern blotting for NF-κB p65 and β-actin. (b) SEG-1 cells were 
transfected with the NF-κB luciferase reporter plasmid, incu-
bated for 24 hours, then treated for an additional 18 hours 
with 50 – 300 μM DCA (left) or with 100 μM DCA, CDCA, 
or TCA (right). Luciferase activity for NF-κB reporter plas-
mid was measured and normalized to beta-galactosidase 
activity. Values shown represent the means ± SD of triplicate 
experiments.BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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induced by DCA in SEG-1 esophageal adenocarcinoma
cells. CAPE, an inhibitor of NF-κB activation, completely
blocked the induction of MUC2 by DCA (Fig. 3). This
result was confirmed using Western Blotting to estimate
changes in protein levels (Fig. 3a) and RT-PCR in MUC2
and NF-κB p65 transcript levels (Fig. 3b). To determine
whether CAPE blocked MUC2 promoter activity, we
employed an MUC2 promoter luciferase construct, which
contains a 2205-bp human MUC2 5'-flanking region
fused to a luciferase reporter gene. After transient transfec-
tion, cells were treated with 100 μM DCA for 18 hours and
luciferase activities were determined (Fig. 3c). CAPE
inhibite MUC2 promoter-driven luciferase activities in
SEG-1 cells treated with DCA.
Whether NF-κB p65 involvement in DCA induced MUC2
activation, it was tested by transfection of NF-κB p65-spe-
cific siRNA into SEG-1 cells. Specific knockdown of
endogenous NF-κB p65 mRNA levels was observed (Fig.
4a, b), and the cells treated with NF-κB p65 siRNA also
showed potent suppression of DC-induced MUC2 activa-
tion detected with in MUC2 transcript levels and Western
Blotting in protein levels (Fig. 4c). To determine whether
NF-κB p65 siRNA blocked MUC2 gene transcription, we
employed an MUC2 promoter luciferase construct. In NF-
κB p65 siRNA SEG-1 cells, after transient transfection
MUC2 promoter luciferase reporter, cells were treated
with 100 μM DCA for 18 hours and luciferase activities
were determined (Fig. 4c), NF-κB p65 siRNA inhibited
MUC2 promoter-driven luciferase activities in SEG-1 cells
treated with DCA. These results suggest that the activity of
NF-κB p65 involved in DCA-induced activation of MUC2
in SEG-1 cells.
Although the precise mechanism by which aspirin inhib-
its esophageal tumorigenesis remains to be elucidated, it
has been reported to inhibits NF-κB nuclear translocation
in the esophageal squamous cell carcinoma cell line[25].
We examined the effect of aspirin, a potential chemopre-
ventive agent in the prevention or treatment of esophageal
cancer, on expression of MUC2 induced by DCA. In SEG-
1 esophageal adenocarcinoma cells treated with DCA
(100 μM) for 18 hours, the basal levels of MUC2 and NF-
κB p65 proteins were decreased by treatment with 4
mmol/L aspirin, there was also partial inhibition of the
bile acid-dependent induction of MUC2 and NF-κB p65
(Fig. 5a). In assays of MUC2 transcription and NF-κB tran-
scriptional activity, aspirin also had effect on basal activ-
ity, and inhibited the bile acid-dependent induction of
MUC2 and NF-κB activity (Fig. 5b).
Involvement of Protein Kinase C but Not Protein Kinase A 
in Induction of MUC2 by DCA
It has been reported that bile acids activate PKC in esopha-
geal adenocarcinoma cells[10,26]. Previous results have
also shown that the PKC inducer PMA and bile acids
increase MUC2 expression in colon carcinoma cell line,
Effect of CAPE on expression of MUC2 Figure 3
Effect of CAPE on expression of MUC2. SEG-1 cells 
were pretreated with or without 10 μg/ml CAPE for 1 h and 
then treated for 18 hours with or without 100 μM DCA. (a) 
Total cellular protein was subjected to Western blotting for 
MUC2 and β-actin. (b) The isolated RNA samples were ana-
lyzed by RT-PCR for MUC2, NF-κB p65 and β-actin. (c) SEG-
1 cells were transfected with MUC2 promoter luciferase 
construct, then treated for 18 hours with or without 100 μM 
DCA in the presence or absence of CAPE. Luciferase activity 
for MUC2 was measured and normalized to beta-galactosi-
dase activity. (means ± SD of triplicate assays, * p < 0.05, for 
inhibition compared with assays without added inhibitor).BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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and that this is prevented by the PKC inhibitor, calphostin
C[27,28]. However, it is unclear whether induction of
MUC2 by bile acids is mediated by PKC in esophageal
adenocarcinoma cells. When SEG-1 cells were treated with
6 nM calphostin C, there was almost complete inhibition
of basal and bile acid-induced MUC2 protein and NF-κB
p65 protein expression (Fig. 6a). This was accompanied
by suppression of MUC2 transcription and of NF-κB tran-
scriptional activity (Fig. 6b). These results indicate that
PKC is involved in the NF-κB dependent induction of
MUC2 expression by DCA.
There has been reported that PKA is involved in bile acid
induce MUC2 expression, and that this is prevented by the
PKA inhibitor, H-8[28]. We also examined the effect on
MUC2 induction by DCA of specific protein kinase inhib-
itor, H-8 (N-[2-(methylamino)ethyl]-5-isoquinolinesul-
Effects of NF-κB p65 siRNA on expression of MUC2 Figure 4
Effects of NF-κB p65 siRNA on expression of MUC2. 
SEG-1 cells were transfected with Nuclear factor-κB (NF-
κB) p65 siRNA, and its effect on NF-κB p65 mRNA was ana-
lyzed using (a) RT-PCR, and (b) Western blotting. (c) Cells 
were treated with 100 μM DCA for 18 hours after exposure 
to siRNA targeting NF-κB p65, (Upper panel) SEG-1 cells 
lysates were analyzed in Western blotting for MUC2 and β-
actin, (Middle panel) The isolated RNA samples were ana-
lyzed by RT-PCR for MUC2, NF-κB p65 and β-actin, (Lower 
panel) SEG-1 cells were transfected with human MUC2 pro-
moter luciferase construct, then treated for 18 hours with or 
without 100 μM DCA after with or without exposure to 
siRNA targeting NF-κB p65. Luciferase activity for MUC2 
was measured and normalized to beta-galactosidase activity. 
(means ± SD of triplicate assays, * p < 0.05, for NF-κB p65 
siRNA compared with assays without NF-κB p65 siRNA).
Effect of aspirin on MUC2 and Nuclear factor-κB (NF-κB)  p65 expression Figure 5
Effect of aspirin on MUC2 and Nuclear factor-κB 
(NF-κB) p65 expression. (a) SEG-1 cells were treated for 
18 hours with or without 100 μM DCA in the presence or 
absence of 4 mmol/L aspirin. Total cellular and nuclear pro-
tein were subjected to Western blotting for MUC2, NF-κB 
p65, and β-actin. (b) SEG-1 cells were transfected with 
human MUC2 promoter luciferase construct or NF-κB luci-
ferase reporter plasmid, then treated for 18 hours with or 
without 100 μM DCA in the presence or absence of 4 mmol/
L aspirin. Luciferase activity for MUC2 or NF-κB was meas-
ured and normalized to beta-galactosidase activity. Values 
shown represent the means ± SD of triplicate experiments.BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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fonamide dihydrochloride). In our study, however, H-8
did not inhibited levels of MUC2 protein and NF-κB p65
protein both in the presence and absence of DCA in SEG-
1 cells (Fig. 7a). There was also not a decrease in MUC2
transcription and in NF-κB transcriptional activity (Fig.
7b). These results suggest that the DCA-dependent induc-
tion of MUC2 depends on PKC but not PKA.
Induction of MUC2 by DCA is not dependent of MAPK
A previous study found that specific inhibitors of MAP
kinase, U0126 and PD98059, inhibited the induction of
MUC2 by bile acids[28]. To investigate the role of MAPK
in the induction of MUC2 and NF-κB by DCA in esopha-
geal adenocarcinoma cells, we examined phosphorylation
of ERK1/2, JNK, P38 kinases and total ERK1/2, JNK, P38
kinases after treatment of SEG-1 cells with 100 μM DCA
for 18 hours. The DCA had effect on the levels of phos-
phorylated ERK1/2, JNK, and P-38 or total ERK1/2, JNK,
and P-38 kinases (Fig. 8). To further investigate the effec-
tion of MAPK on the induction of MUC2 and NF-κB, we
Effect of calphostin C on MUC2 and NF-κB p65 expression Figure 6
Effect of calphostin C on MUC2 and NF-κB p65 
expression. SEG-1 cells were treated for 18 hours with or 
without 100 μM DCA in the presence or absence of 5 nM 
calphostin C. (a) Total cellular and nuclear protein were sub-
jected to Western blotting for MUC2, NF-κB p65, and β-
actin. (b) SEG-1 cells were transfected with MUC2 promoter 
Luciferase construct or NF-κB Luciferase reporter plasmid, 
then treated for 18 hours with or without 100 μM DCA in 
the presence or absence of 5 nM calphostin C. Luciferase 
activity for MUC2 or NF-κB was measured and normalized 
to beta-galactosidase activity. (means ± SD of triplicate 
assays, * p < 0.05, for inhibition compared with assays with-
out added inhibitor).
Effect of H-8 on MUC2 and NF-Kb p65 expression Figure 7
Effect of H-8 on MUC2 and NF-Kb p65 expression. (a) 
SEG-1 cells were treated for 18 hours with or without 100 
μM DCA in the presence or absence of 5 μM H-8. Total cel-
lular protein and nuclear protein were subjected to Western 
blotting for MUC2, NF-κB p65, and β-actin. (b) SEG-1 cells 
were transfected with the MUC2 promoter luciferase con-
struct or the NF-κB luciferase reporter plasmid, then treated 
for 18 hours with or without 100 μM DCA in the presence 
or absence of 5 μM H-8. Luciferase activity for MUC2 or NF-
κB was measured and normalized to beta-galactosidase activ-
ity. Values shown represent the mean and standard error of 
the mean of triplicate experiments.BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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used U0126 and PD98059 to selectively block the activity
of MAPK, we found that these inhibitors did not block the
DCA-dependent increase in MUC2 protein and NF-κB
protein, although both U0126 and PD98059 did suppress
phosphorylation of ERK1/2, JNK, and P38. These results
suggest that expression of MUC2 and NF-κB treated with
DCA is not dependent on MAPK in SEG-1.
Discussion
The effects of bile acids on mucin gene expression in
esophageal adenocarcinoma cells have not been well
studied. Bile acids has been reported to increase the secre-
tion of MUC2 in esophageal cells[29], but MUC2 gene
expression and the molecular events responsible for
MUC2 gene expression were not studied in esophageal
adenocarcinoma cells. In the current study, we find that
bile acids increase MUC2 expression in SEG-1 esophageal
adenocarcinoma cells, and the transcriptional activity of
MUC2 promoter reporter construct transiently transfected
into SEG-1 was increased by DCA and other bile acids in
a dose-dependent fashion, indicating that bile acid-
induced MUC2 up-regulation occurs at the transcriptional
level.
NF-κB is an important transcription factor that mediates
expression of multiple genes in important biologic proc-
esses including cell growth, apoptosis, and transforma-
tion [30-32]. We postulated that NF-κB could play a role
in the induction of MUC2 by bile acids. Our data indicate
that CAPE, an inhibitor of NF-κB translocation, it reduced
endogenous as well as bile acid up-regulated MUC2 tran-
scription, in addition NF-κB expression and transcription
activity coincided with MUC2 induction, and inhibition
of NF-κB expression and activity efficiently suppressed
bile acid-mediated up-regulation of MUC2, indicating
that NF-κB is involved in MUC2 transcription induced by
bile acid. Furthermore, it is confirmed by NF-κB p65
siRNA can also blocked MUC2 expression induced by bile
acid. Activation of NF-κB is mediated through phosphor-
ylation, ubiquination, and subsequent degradation of
inhibitor IκB, this enables the free NF-κB p65 to translo-
cate to the nucleus and activate target genes[33]. Our
study shows that NF-κB p65 expression can be induced by
DCA, suggesting degradation of inhibitor IκB may be
involved in this pathway. Previous studies have indicated
that NF-κB is involved in expression of MUC2[34,35], as
the transcriptional competence of the NF-κB cis element
was demonstrated containing the same region of the
MUC2 promoter from bases ~1528 to ~1307 [27], impli-
cating MUC2 promoter may be activated via expression of
NF-κB induced by bile acids. Other transcription factors
that have been shown to regulate MUC2 expression in
other contexts include SP-1, CDX-2, and GATA-5 [36-38].
It is likely that these transcription factors activities may be
also required for MUC2 expression in esophageal adeno-
carcinoma cells, but this has not yet been established.
The transcriptional activity of NF-κB is also enhanced
directly by phosphorylation at various sites on its subu-
nits. The kinases responsible for these phosphorylations
may include PKA, and PKC. Activation of PKC by bile
acids is well documented, and may be one mechanism of
bile acid induced carcinogenesis [10,26]. We found that
the PKC inhibitor calphostin C strongly blocked NF-κB
and MUC2 induction by DCA, indicating that PKC is
involved in the bile acid-dependent induction of MUC2.
PKA has been reported that it is involved in bile acids
stimulate MUC2 expression, although the bile acid-
dependent induction of MUC2 depends less on PKA than
on PKC[28]. However, our data indicated that the protein
kinase A inhibitor, H-8, is not effective in blocking bile
acid dependent induction of MUC2 and NF-κB, suggest-
Effect of U0126 and PD98059 on MUC2 and NF-κB p65  expression Figure 8
Effect of U0126 and PD98059 on MUC2 and NF-κB 
p65 expression. SEG-1 cells were treated for 18 hours 
with or without 100 μM DCA in the presence or absence of 
8 μM U0126 and 60 μM PD98059. Total cellular and nuclear 
protein were subjected to Western blotting for MUC2, NF-
κB p65, phosphorylation of ERK1/2, JNK, P-38, and total 
ERK1/2, JNK, P-38 and β-actin.BMC Cancer 2008, 8:333 http://www.biomedcentral.com/1471-2407/8/333
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ing expression of MUC2 induced by DCA independent on
PKA. In contrast to previous work on MUC2 induction by
PMA via the ERK cascade, we find that the induction of
MUC2 by bile acid is independent of MAP kinases in SEG-
1 esophageal adenocarcinoma cells. Although treatment
with DCA did affect the phosphorylation of ERK1/2, JNK,
and P38 Kinase, U0126 and PD5089, inhibitors of MAP
kinase, did not block MUC2 and NF-κB induction by DCA
in SEG-1 cells, indicating MUC2 induction by DCA inde-
pendent on the MAPK cascade.
Conclusion
We conclude that treatment of human esophageal adeno-
carcinoma cells with DCA, up regulates MUC2 transcrip-
tion by activation of NF-κB via PKC but not PKA,
independent of MAP kinase. The biologic consequences
of the induction of MUC2 expression by bile acids are
unclear. Further studies are needed to confirm that
whether induction of MUC2 by bile acids can increase the
invasion potential of cells and their metastatic potential
in vitro and in vivo. A more detailed understanding of the
precise mechanisms by which bile acids induce MUC2
could also facilitate the development of chemopreventive
strategies to diminish the risk of carcinogenesis and
metastasis, particularly in esophageal adenocarcinoma.
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